type 2 diabetes and received a comprehensive evaluation including lifestyle choices, anthropometry, cardiometabolic parameters, complications screening including peripheral neuropathy, retinopathy testing, comorbidity profiling, and had fasting blood samples taken for glucose, lipids and other clinical biomarkers. The median fasting blood glucose level among cases was 9.8 (IQR 5.9-12.5) mmol/L, and four out of five cases took metformin and/or a sulphonylurea as their main glucose-lowering medication. The study revealed high prevalences of complications despite a relatively short known duration of diabetes: the metabolic syndrome (78%), hypertension (71%), cataracts (32%), obesity (27%), hyperlipidaemia, neurological deficits including sensory deficits (46% by history), and 35% of men had erectile dysfunction. As expected, risk factors for these findings indicated that in combination or in cases as a separate risk factor, older age, BMI, and longer duration of diabetes were associated with many of the defined complications and comorbidities. A degree of heterogeneity of risk factor associations across SSA was inevitable.
This was an impressive study and builds on the findings of the previous Diabcare Africa Study [5] . The current study, however, provides more precise diabetes prevalences data and risk factor identification, and represents the largest cross-sectional study of type 2 diabetes and its associations with complications and comorbidities. These data suggest that a high proportion of cases are diagnosed with diabetes late in the evolution of the condition and along with the high prevailing rates of hyperglycaemia provide a part explanation for high microvascular rates. In addition, the high rates of hypertension, hyperlipidaemia and obesity in individuals with poor glycaemia control provide a platform for developing cardiovascular disease and stroke which are now emerging as increasing causes of death in SSA.
Further research to complete important gaps in the nature of type 2 diabetes in SSA and how it is managed would need to include regional variations in the application of diagnostic criteria, the use of HbA1c as a marker of diabetes control, how health services are accessed and resourced, and establishing disease registries and longitudinal studies to more accurately interpret risk factor influences.
It is abundantly clear that the burden of type 2 diabetes in SSA is now immense and that national and international public health interventions are necessary. Structured pathways that include earlier screening for diabetes, offering inexpensive medications, and implementing an integrated clinic system that deals with diagnosis, risk factor identification, and complications should enable patients to access a minimal level of diabetes care in one setting. An educational initiative to underpin and enhance success of public health measures is urgently required at the individual, health professional level, and health provider level. A focus on complications prevention will be essential to reduce total healthcare costs attributable to diabetes in SSA which have been estimated to be between US$35 billion to US$59 billion by 2030 [2] . Achieving success in terms of improved well being and greater life expectancy of sub-Saharan Africans with diabetes will not only require the above measures but a wider implementation of initiatives such as the WHO Global Action Plan for the Prevention and Treatment of non-communicable disease (NCDs), 2013-2020 and its successors [6] . Such ambitions require significantly higher funding levels and this continues to represent a key obstacle in one of the most economically deprived areas of the world.
